Skip to main content

Table 3 Significant effect of clinical variables on clinical outcomes

From: Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients

Clinical variables

Clinical outcomes

P

OR/HR (95% CI)

Risk stratifications

OS (mean day ± SE)

0.027

 

 Low + intermediate

1473 ± 82

 

1.00 (reference)

 High

1048 ± 113

 

2.325 (1.103–4.900)

Risk stratifications

PFS (mean day ± SE)

0.013

 

 Low

1532 ± 151

 

1.00 (reference)

 Intermediate

1096 ± 99

0.056

2.762 (0.974–7.834)

 High

740 ± 105

0.005

4.801 (1.606–14.350)

Platelets, ×109/L

CR (%)

  

 < 38.5

78.6

 

1.00 (reference)

 ≥ 38.5

92.2

0.006

3.225 (1.362–7.635)

Risk stratifications


Liver function damage (%)

0.009

 

 Low

22.9

 

1.00 (reference)

 Intermediate

5.9

0.008

0.213 (0.071–0.638)

 High

15.1

0.355

0.660 (0.202–1.784)

Risk stratifications

Cardiotoxicity (%)

0.004

 

 Low

17.1

 

1.00 (reference)

 Intermediate

2.5

0.005

0.126 (0.030–0.535)

 High

3.8

0.079

0.190 (0.036–1.001)

  1. CR complete remission, OS overall survival, RFS relapse-free survival, CI confidence interval, HR hazard ratio, OR odd risk, SE standard error